A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

被引：0
|
作者：
Scheulen, M. [1 ]
Mross, K. [2 ]
Richly, H. [1 ]
Nokay, B. [1 ]
Frost, A. [2 ]
Scharr, D. [2 ]
Lee, K. H. [3 ]
Saunders, O. [3 ]
Hilbert, J. [4 ]
Fietz, O. [3 ]
机构：
[1] Univ Essen Gesamthsch, W German Canc Ctr, Innere Klin Tumorforsch, Essen, Germany
[2] Univ Freiburg, Tumour Biol Ctr, Freiburg, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Clin Res, Biberach, Germany
[4] Boehringer Ingelheim Pharmaceut Inc, Clin Pharmacokinet Pharmacodynam, Ridgefield, CT USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72203-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [1] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
    Scheulen, M. E.
    Mross, K. B.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors
    Mross, K. B.
    Scheulen, M. E.
    Frost, A.
    Scharr, D.
    Richly, H.
    Nokay, B.
    Lee, K.
    Hilbert, J.
    Fleischer, F.
    Fietz, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Mross, Klaus
    Richly, Heike
    Frost, Annette
    Scharr, Dirk
    Nokay, Bahar
    Graeser, Ralph
    Lee, Chooi
    Hilbert, James
    Goeldner, Rainer-George
    Fietz, Oliver
    Scheulen, Max E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 405 - 417
  • [4] Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours
    Delord, J. P.
    Tourani, J. M.
    Lefresne, F.
    Petain, A.
    Pouget, J. -C.
    Ravaud, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 647 - 656
  • [5] Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours
    J. P. Delord
    J. M. Tourani
    F. Lefresne
    A. Pétain
    J.-C. Pouget
    A. Ravaud
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 647 - 656
  • [6] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Klaus Mross
    Heike Richly
    Annette Frost
    Dirk Scharr
    Bahar Nokay
    Ralph Graeser
    Chooi Lee
    James Hilbert
    Rainer-George Goeldner
    Oliver Fietz
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 405 - 417
  • [7] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    Diaz-Padilla, I.
    Siu, L. L.
    San Pedro-Salcedo, M.
    Razak, A. R. A.
    Colevas, A. D.
    Shepherd, F. A.
    Leighl, N. B.
    Neal, J. W.
    Thibault, A.
    Liu, L.
    Lisano, J.
    Gao, B.
    Lawson, E. B.
    Wakelee, H. A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 604 - 611
  • [8] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    L L Siu
    M San Pedro-Salcedo
    A R A Razak
    A D Colevas
    F A Shepherd
    N B Leighl
    J W Neal
    A Thibault
    L Liu
    J Lisano
    B Gao
    E B Lawson
    H A Wakelee
    British Journal of Cancer, 2012, 107 : 604 - 611
  • [9] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
    Christian Dittrich
    Michael A. Fridrik
    Robert Koenigsberg
    Chooi Lee
    Rainer-Georg Goeldner
    James Hilbert
    Richard Greil
    Investigational New Drugs, 2015, 33 : 409 - 422
  • [10] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
    Dittrich, Christian
    Fridrik, Michael A.
    Koenigsberg, Robert
    Lee, Chooi
    Goeldner, Rainer-Georg
    Hilbert, James
    Greil, Richard
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 409 - 422
12345